BRIDGEWATER, N.J., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ:VLRX), the maker of V-Go®, the only daily insulin delivery device worn like a patch, announced today that CEO John Timberlake appeared as a guest this morning on Fox Business Network’s show, “Morning with Maria”.
Mr. Timberlake and Joe Dougherty, a patient with Type 2 diabetes, were interviewed about Valeritas’ unique V-Go® Wearable Insulin Delivery Device.
V-Go is a small, disposable, easy-to-use insulin delivery device that is worn like a patch for 24 hours. Patients using this discreet technology no longer have to carry insulin syringes or pens for mealtime dosing. When first applied and with the push of a button, V-Go begins delivering a steady dose of insulin throughout the day. During meals and snacks, users can discreetly press another button on the device to deliver more insulin.
V-Go can be worn inconspicuously under clothing anywhere on the body where insulin can be injected. Common sites are the abdomen, upper outer arm or top of thigh.
Patients using V-Go can go about their normal daily activities, such as working, shopping, exercising, bathing and sleeping without having to inject insulin multiple times a day.
Of the approximately 5.6 million patients with Type 2 diabetes who require daily insulin, nearly 4.5 million, or 80%, are not achieving the American Diabetes Association blood sugar goal of <7%, making them V-Go candidates.
V-Go has demonstrated significant reductions in blood sugar levels in patients who switched from multiple daily injections of insulin. Additionally, with V-Go, less insulin was used than prior insulin regimens prescribed before starting V-Go.
About Valeritas Holdings, Inc.
Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, wearable, basal-bolus insulin delivery device for patients with type 2 diabetes that enables patients to administer a continuous preset basal rate of insulin over 24 hours. It also provides discreet on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed for the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Marlborough, Massachusetts.
More information is available at www.valeritas.com and our Twitter feed @Valeritas_US, www.twitter.com/Valeritas_US.
Forward-Looking Statements
This press release may contain forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to Valeritas technologies, business and product development plans and market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue Valeritas’ business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize the V-Go® Wearable Insulin Delivery device with limited resources, competition in the industry in which Valeritas operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and Valeritas assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents Valeritas files with the SEC available at www.sec.gov.
Investor Contacts:
Lynn Pieper Lewis or Greg Chodaczek
Gilmartin Group
610-368-6505
ir@valeritas.com
Media Contact:
Kevin Knight
Knight Marketing Communications, Ltd.
(206) 451-4823
pr@valeritas.com